Swiss National Bank increased its holdings in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 19.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 173,160 shares of the biopharmaceutical company’s stock after acquiring an additional 27,800 shares during the period. Swiss National Bank owned approximately 0.17% of Sangamo Therapeutics worth $2,459,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in SGMO. First Mercantile Trust Co. grew its holdings in Sangamo Therapeutics by 93.7% during the first quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 3,708 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in Sangamo Therapeutics during the second quarter worth $155,000. Wealthcare Advisory Partners LLC acquired a new position in Sangamo Therapeutics during the first quarter worth $190,000. Amalgamated Bank grew its holdings in Sangamo Therapeutics by 38.4% during the second quarter. Amalgamated Bank now owns 15,478 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 4,294 shares during the period. Finally, Element Capital Management LLC acquired a new position in Sangamo Therapeutics during the first quarter worth $240,000. 63.97% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics stock opened at $14.45 on Thursday. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -20.64 and a beta of 2.95. Sangamo Therapeutics Inc has a fifty-two week low of $11.30 and a fifty-two week high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm’s revenue for the quarter was up 159.6% on a year-over-year basis. During the same period last year, the company posted ($0.17) EPS. equities analysts predict that Sangamo Therapeutics Inc will post -0.69 EPS for the current year.

A number of research analysts recently weighed in on SGMO shares. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. Cowen reissued a “buy” rating on shares of Sangamo Therapeutics in a report on Monday, July 23rd. Bank of America assumed coverage on Sangamo Therapeutics in a report on Wednesday, June 20th. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Wedbush reissued a “hold” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, August 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $21.00.

In other news, Director H Stewart Parker bought 2,000 shares of the stock in a transaction on Friday, September 7th. The shares were bought at an average price of $13.52 per share, with a total value of $27,040.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of the stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $14.17, for a total value of $70,850.00. The disclosure for this sale can be found here. Insiders sold 30,000 shares of company stock worth $446,250 in the last three months. 1.20% of the stock is owned by corporate insiders.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Article: Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.